8-K: SELLAS Life Sciences Reports Positive Clinical Trial Updates and First Quarter 2024 Financial Results

SELLAS Life Sciences announced positive clinical trial updates for its lead drug candidates and reported its first quarter 2024 financial results.

Summary

• SELLAS Life Sciences reported its financial results for the first quarter ended March 31, 2024, and provided a corporate update.
• The company's Phase 3 REGAL study for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) has completed enrollment and the Independent Data Monitoring Committee (IDMC) recommended the trial continue without modifications.
• The IDMC will reconvene in June to review data from all 127 enrolled patients.
• Positive Phase 2 data for SLS009 in relapsed/refractory AML showed a 100% response rate in patients with the ASXL1 mutation at the 30 mg BIW dose.
• SLS009 demonstrated 62% anti-leukemic activity across all dose levels.
• SELLAS has filed a provisional patent application based on the SLS009 efficacy data in r/r AML patients with ASXL1 mutation.
• A Phase 1b/2 clinical trial of SLS009 in combination with a BTK inhibitor in relapsed/refractory DLBCL has commenced in China, funded by GenFleet Therapeutics.
• The company's research and development expenses decreased to $5.1 million in Q1 2024 from $7.2 million in Q1 2023.
• General and administrative expenses increased slightly to $4.5 million in Q1 2024 from $4.1 million in Q1 2023.
• The net loss for Q1 2024 was $9.6 million, or $0.21 per share, compared to a net loss of $11.1 million, or $0.47 per share, in Q1 2023.
• As of March 31, 2024, SELLAS had $18.4 million in cash and cash equivalents.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical trial results and improved financial metrics. The 100% response rate in a specific patient subgroup for SLS009 is a significant positive, and the IDMC recommendation to continue the Phase 3 REGAL study is also encouraging. The company's cash position is also strong. However, the company is still in the clinical trial phase and faces risks associated with drug development.

Positives

• The IDMC recommended the Phase 3 REGAL study to continue without modifications, indicating positive progress.
• SLS009 showed a 100% response rate in r/r AML patients with ASXL1 mutation at the 30 mg BIW dose, demonstrating strong efficacy.
• The company has a strong cash position of $18.4 million.
• The net loss per share improved year-over-year, indicating better financial performance.
• A new patent application was filed based on the positive SLS009 data.

Negatives

• The company experienced a net loss of $9.6 million in Q1 2024.
• General and administrative expenses increased slightly compared to the same period last year.

Risks

• The company is still in the clinical trial phase, and there is no guarantee of regulatory approval for its drug candidates.
• The company is dependent on the success of its clinical trials and may face setbacks.
• The company's financial position is still reliant on further funding and may face challenges if it cannot secure additional capital.
• The company is subject to risks and uncertainties associated with oncology product development and clinical success.

Future Outlook

The company expects further significant catalysts throughout 2024, including additional data from the SLS009 trials and the next IDMC meeting for the REGAL study. Initial safety and efficacy data from the National Institute of Health PIVOT program in Pediatric Tumors are expected to be reported throughout 2H 2024.

Management Comments

• Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, stated that the company had a very productive and successful first quarter of 2024.
• Dr. Stergiou highlighted the strong preliminary data from the Phase 2a study of SLS009 in r/r AML, including a 100% response rate in patients with ASXL1 mutation.
• Dr. Stergiou expressed excitement about the ongoing progress in the Phase 3 REGAL study of GPS and the IDMC's recommendation to continue the trial without modification.

Industry Context

This announcement is significant in the context of the biopharmaceutical industry, where positive clinical trial results are crucial for company valuation and future funding. The positive data for SLS009, particularly in a difficult-to-treat patient population, positions SELLAS as a potential player in the AML treatment landscape. The collaboration with GenFleet and BeiGene also highlights the growing trend of international partnerships in drug development.

Comparison to Industry Standards

• The 100% response rate in the ASXL1 mutation subgroup for SLS009 is very promising and exceeds typical response rates seen in relapsed/refractory AML treatments.
• For example, standard chemotherapy regimens often have response rates below 50% in this setting.
• The progress of the Phase 3 REGAL study is also a positive sign, as many oncology trials face challenges in enrollment and data collection.
• Companies like Agios Pharmaceuticals and Jazz Pharmaceuticals are also developing treatments for AML, and SELLAS's results will be closely watched in comparison to their progress.
• The collaboration with GenFleet and BeiGene is similar to other partnerships in the industry, where companies leverage each other's expertise and resources to accelerate drug development.

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical trial results and improved financial metrics.
• Employees may feel more secure about the company's future prospects.
• Patients with AML may benefit from the potential new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The IDMC will reconvene in June 2024 to review data from all 127 enrolled patients in the Phase 3 REGAL study.
• Enrollment is ongoing in the 30 mg BIW cohort with ASXL1 mutation for the SLS009 study.
• Initial safety and efficacy data from the National Institute of Health PIVOT program in Pediatric Tumors are expected to be reported throughout 2H 2024.

Key Dates

Keywords

SELLAS Life Sciences, Galinpepimut-S, SLS009, Acute Myeloid Leukemia, AML, CDK9 inhibitor, Clinical Trial, Biopharmaceutical, Cancer Therapy, ASXL1 mutation